RecallRadar

FDA Drug recall D-0464-2021

Nadolol Tablets, USP 40 mg 100 Tablets Rx Only NDC 69097-868-07 Manufactured for: Cipla USA Inc. 9100 S. Dadeland Blvd., Suite 1599 Miami,…

On 2021-06-02 the FDA classified a Class II recall of Nadolol Tablets, USP 40 mg 100 Tablets Rx Only NDC 69097-868-07 Manufactured for: Cipla USA Inc. 9100 S. Dadeland Blvd., Suite 1599 Miami,… by Cardinal Health, citing CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0464-2021
ClassificationClass II
Statusterminated
Initiated2021-03-15
Published2021-06-02
Last updated2026-09-13 11:52 UTC
CompanyCardinal Health
DistributionFL, GA, SC

Product

Nadolol Tablets, USP 40 mg 100 Tablets Rx Only NDC 69097-868-07 Manufactured for: Cipla USA Inc. 9100 S. Dadeland Blvd., Suite 1599 Miami, FL 33156

Reason

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Identifiers

ndc69097-867-07
ndc69097-867-15
ndc69097-867-02
ndc69097-868-02
ndc69097-868-07
ndc69097-868-15
ndc69097-869-02
ndc69097-869-07
ndc69097-869-15
code_infoNB100156

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0464-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.